This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial
Kamphuis, P. J. G. H.,
Verhey, F. R. J.,
Olde Rikkert, M. G. M.,
Twisk, J. W. R.,
Swinkels, S. H. N.,
Scheltens, P.
Objective: To investigate the extent that baseline cognitive impairment and intake adherence affected the 13-item Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog) intervention response of a medical food in Alzheimer’s Disease (AD) patients. DESIGN/SETTING/PARTICIPANTS /INTERVENTION/MEASUREMENTS: This analysis was performed on data from a proof-of-concept study, consisting of a 12-week, double-blind, randomized, controlled, multicenter trial, […]
Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial
Kamphuis, P. J. G. H.,
Verhey, F. R. J.,
Olde Rikkert, M. G. M.,
Twisk, J. W. R.,
Swinkels, S. H. N.,
Scheltens, P.
Objectives: To investigate the effect of a medical food (Souvenaid) on body mass index (BMI) and functional abilities in patients with mild Alzheimer’s disease (AD). DESIGN/SETTING/PARTICIPANTS/INTERVENTION /MEASUREMENTS: These analyses were performed on data from a 12-week, double-blind, randomized, controlled, multicenter, proof-of-concept study with a similarly designed and exploratory 12-week extension period. Patients with mild AD […]
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies
Harrington, C.,
Sawchak, S.,
Chiang, C.,
Davies, J.,
Donovan, C.,
Saunders, A. M.,
Irizarry, M.,
Jeter, B.,
Zvartau-Hind, M.,
van Dyck, C. H.,
Gold, M.
Introduction: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). An open-label extension study (REFLECT-4) assessed RSG XR long-term safety.; […]
Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer’s disease
Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD).; Methods: Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm(2)]), […]
Memantine in everyday clinical practice: a comparison of studies in Germany and Greece
Förstl, H.,
Stamouli, S. S.,
Janetzky, W.,
Galanopoulos, A.,
Karageorgiou, C.,
Tzanakaki, M.
Background/aims: Results from German and Greek non-interventional studies were compared to investigate possible differences concerning efficacy, tolerability and compliance between both countries.; Methods: In two open-label, multicentre, non-interventional studies, 4,305 patients with mild to severe Alzheimer’s disease (AD) were treated with daily doses of 20 mg memantine for 6 months. Efficacy was assessed using the […]
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Farlow, Martin,
Veloso, Felix,
Moline, Margaret,
Yardley, Jane,
Brand-Schieber, Elimor,
Bibbiani, Francesco,
Zou, Heng,
Hsu, Timothy,
Satlin, Andrew
Background: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer’s disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detailed analysis of the safety and tolerability of increasing […]